MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by GENENTA SCIENCE SPA

News headline image
Genenta Announces Strategic Transformation into a Biotech, Defense, Aerospace, and National Security Industrial Consolidator
From GENENTA SCIENCE SPA
Via GlobeNewswire
Tickers GNTA
News headline image
Genenta Science Provides Update on CEO Ownership
From GENENTA SCIENCE SPA
Via GlobeNewswire
Tickers GNTA
News headline image
Genenta Reports Long-Term Survival Trends and Immune Findings in Brain Tumor (GBM) Trial
From GENENTA SCIENCE SPA
Via GlobeNewswire
Tickers GNTA
News headline image
Genenta Announces Pricing of $15.0 Million Registered Direct Offering of American Depositary Shares
From GENENTA SCIENCE SPA
Via GlobeNewswire
Tickers GNTA
News headline image
Genenta and Anemocyte Announce Strategic Partnership to Advance Off-The-Shelf LVV Plasmid DNA Production
From GENENTA SCIENCE SPA
Via GlobeNewswire
Tickers GNTA
News headline image
Genenta Announces Long-Term Follow-Up Observations in Brain Tumor (GBM) Study with Emerging Survival Signals
From GENENTA SCIENCE SPA
Via GlobeNewswire
Tickers GNTA
News headline image
Genenta Showcases Strategic Vision at Premier Biotech Forum in Qatar
From GENENTA SCIENCE SPA
Via GlobeNewswire
Tickers GNTA
News headline image
Genenta Announces €20 million ($21.9M) Financing To Expand Pipeline As Brain Tumor Trial Is Showing Promising Survival Rates
From GENENTA SCIENCE SPA
Via GlobeNewswire
Tickers GNTA
News headline image
Genenta Strengthens Agreement with AGC Biologics to Boost Cell Therapy Manufacturing
From GENENTA SCIENCE SPA
Via GlobeNewswire
Tickers GNTA
News headline image
Genenta’s CEO to present at the U.S. Senate meeting on “Cross-Border Investments and Strategies in the Biotechnology Sector: A Transatlantic Perspective”
From GENENTA SCIENCE SPA
Via GlobeNewswire
Tickers GNTA
News headline image
Genenta Secures Approval for Innovative Trial for Metastatic Renal Cell Cancer
From GENENTA SCIENCE SPA
Via GlobeNewswire
Tickers GNTA
News headline image
Genenta Welcomes New Directors John L. Cantello, Lauren H. Chung, Armon R. Sharei, and Todd Wider
From GENENTA SCIENCE SPA
Via GlobeNewswire
Tickers ARYD GNTA SQZ
News headline image
Genenta Demonstrated Reprogramming of the Tumor Microenvironment in GBM Patients, Paving the Way for Innovative Treatments of Solid Tumors
From GENENTA SCIENCE SPA
Via GlobeNewswire
Tickers GNTA
News headline image
Genenta to Present at Upcoming Scientific and Investor Conferences
From GENENTA SCIENCE SPA
Via GlobeNewswire
Tickers GNTA
News headline image
Genenta Announces Ongoing Clinical Trial Progress and Proposed Expansion in Solid Tumor Treatments
From GENENTA SCIENCE SPA
Via GlobeNewswire
Tickers GNTA
News headline image
The European Commission Grants Orphan Drug Designation to Temferon™ for Treatment of Glioma
From GENENTA SCIENCE SPA
Via GlobeNewswire
Tickers GNTA
News headline image
Genenta to Provide Update on Lead Product Temferon™
From GENENTA SCIENCE SPA
Via GlobeNewswire
Tickers GNTA
News headline image
Genenta Announces Fiscal Year 2022 Financial Results and Annual Report on Form 20-F Filing
From GENENTA SCIENCE SPA
Via GlobeNewswire
Tickers GNTA
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story